affimiumAffinium is a specialty pharmaceutical company developing a new class of antibiotics that targets FabI in the bacterial fatty acid synthesis pathway AFN-1252, the lead clinical compound, is a first-in-class antibiotic for both oral and IV treatment of staphylococcal infections. AFN 1252 has highly potent activity only against staphylococci, including MRSA and all other drug resistant strains, and therefore may protect from off-target, negative effeccts of broader spectrum agents.

1 Comment

August 8, 2013 · 10:13 pm

One response to “Affinium

  1. Definitely imagine that that you stated. Your favorite justification appeared to be at the net the simplest factor to understand of.
    I say to you, I definitely get annoyed whilst other people think about worries that they just
    do not recognise about. You controlled to hit the nail upon the top
    and defined out the whole thing with no need side-effects
    , other folks can take a signal. Will likely be again to get more.
    Thank you

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s